Business Context and Reporting Period
Cormedix Inc. filed a Form 8-K Current Report on May 23, 2013, regarding a material definitive agreement entered into on that date. The company is a Delaware corporation focused on the development and commercialization of its product, Neutrolin.
Key Financial Metrics and Transaction Details
- Transaction Type: Sale of senior secured convertible notes and warrants to existing institutional investors.
- Principal Amount: $1,500,000 in notes.
- Gross Proceeds: $1,425,000 (reflecting a 5% discount).
- Interest Rate: 8.0% per annum.
- Warrants: 1,000,000 shares exercisable at $1.10 per share, exercisable one year after issuance with a five-year term.
- Use of Proceeds: General corporate purposes, development and commercialization of Neutrolin, working capital, and capital expenditures.
- Liquidity/Collateral: Gross proceeds are deposited into a cash collateral account subject to a first priority security interest. Funds are released upon receipt of a CE Mark for Neutrolin.
Material Changes and Terms
The filing details the creation of a direct financial obligation with specific repayment and conversion terms:
- Repayment Structure: Notes are to be redeemed in eight equal monthly installments beginning September 1, 2013, and ending April 1, 2014. The company may elect to pay installments in cash or shares of common stock based on a specific pricing formula.
- Conversion Terms: Notes are convertible at $1.10 per share, subject to a full-ratchet anti-dilution provision. Conversion is restricted if it results in beneficial ownership exceeding 4.99% or 9.99% (at holder election).
- Stockholder Approval: Issuance of shares upon conversion or warrant exercise is capped at 20% of outstanding shares (2,640,528 shares) unless stockholder approval is obtained by July 30, 2013.
- Default Provisions: In the event of default, noteholders may require redemption at 125% of the amount due. If the default is due to bankruptcy or insolvency, all amounts become immediately due and payable.
- Redemption Option: If a CE Mark for Neutrolin is not received by July 31, 2013, noteholders may require redemption of the notes at par value plus accrued interest.
Guidance, Risks, and Contingencies
The filing highlights several material risks and contingencies:
- Regulatory Contingency: The release of cash collateral and the avoidance of a mandatory redemption option by noteholders are contingent on receiving a CE Mark for Neutrolin by July 31, 2013.
- Dilution Risk: The transaction includes full-ratchet anti-dilution protection, which could significantly lower the conversion price if the company issues equity at a lower price in the future.
- Ownership Caps: Beneficial ownership limitations (4.99% or 9.99%) restrict the ability of holders to convert notes or exercise warrants immediately if it would exceed these thresholds.
- Closing Conditions: The transaction is expected to close on or before May 31, 2013, subject to customary closing conditions.
Investor Verification Checklist
- Verify the status of the CE Mark application for Neutrolin and the likelihood of approval by July 31, 2013.
- Confirm the company's ability to secure stockholder approval for the 20% issuance overage by July 30, 2013.
- Review the company's current cash position to assess its ability to meet the monthly installment payments starting September 2013 if it cannot pay in stock.
- Monitor future equity issuances that could trigger the full-ratchet anti-dilution provision and lower the conversion price.
- Check for any subsequent filings regarding the actual closing date and final terms of the securities purchase agreement.